Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2775-2780

  Gomes, Marisa Z R ^a,b   Jiang, Ying ^a   Mulanovich, Victor E ^a   Lewis, Russell E ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLOFARABINE; CYTARABINE; ECHINOCANDIN; FLUCONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLUS; CANCER CHEMOTHERAPY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; DRUG EFFECTS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROCEDURES; RISK FACTOR;

AGED; ANTIFUNGAL AGENTS; ASPERGILLUS; ECHINOCANDINS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRIAZOLES; VORICONAZOLE;

EID: 84898618434     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01527-13     Document Type: Article

References (21)

1. Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA. 2012. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/ itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 97:459-463. http://dx.doi.org/10.3324/haematol.2011.051995.
2. Auberger J, Lass-Florl C, Aigner M, Clausen J, Gastl G, Nachbaur D. 2012. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J. Antimicrob. Chemother. 67: 2268-2273. http://dx.doi.org/10.1093/jac/dks189.
3. Gomes MZ, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP. 25 November 2013. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob. Agents Chemother. http://dx.doi.org/10. 1128/AAC.01525-13.
4. Rogers TR, Slavin MA, Donnelly JP. 2011. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Br. J. Haematol. 153:681-697. http://dx.doi.org/10.1111/j.1365-2141.2011.08650.x.
5. Kontoyiannis DP. 2012. Invasive mycoses: strategies for effective management. Am. J. Med. 125:S25-S38. http://dx.doi.org/10.1016/j.amjmed.2011.10. 009.
6. Cornely OA, Bohme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Kruger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ. 2009. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113-122. http://dx.doi.org/10. 3324/haematol.11665.
7. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. 2011. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support. Care Cancer 19:19-26. http://dx.doi.org/10. 1007/s00520-009-0783-3.
8. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821. http://dx.doi.org/10.1086/588660.
9. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. 2012. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J. Clin. Oncol. 30:2492-2499. http://dx.doi.org/10.1200/JCO.2011.37.9743.
10. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. 2006. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45-51. http://dx.doi.org/10.1182/blood-2005-08-3294.
11. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. 2012. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118:4471-4477. http://dx.doi.org/10.1002/ cncr.27429.
12. Tran H, Yang D. 2012. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults. Ann. Pharmacother. 46:89-96. http://dx.doi.org/10.1345/aph.1Q295.
13. Tiley S, Claxton D. 2013. Clofarabine in the treatment of acute myeloid leukemia in older adults. Ther. Adv. Hematol. 4:5-13. http://dx.doi.org/10.1177/ 2040620712461666.
14. UK Medicines and Healthcare Products Regulatory Agency (MHRA). 2011 (updated 12 March 2013). Summary of product characteristics (Evoltra 1mg/ml concentrate for solution for infusion). http://www.medicines.org.uk/EMC/ medicine/18023/SPC/Evoltra-1mg-ml-concentrate-for-solution-for-infusion/. Accessed 17 November 2013.
15. Lewis RE. 2012. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. Am. J. Ther. 19:51-63. http://dx.doi.org/10.1097/MJT.0b013e3181ff7e10.
16. Lewis RE. 2011. Current concepts in antifungal pharmacology. Mayo Clin. Proc. 86:805-817. http://dx.doi.org/10.4065/mcp.2011.0247.
17. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. http://dx.doi.org/10.1016/S0140-6736(03)14472-8.
18. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. 2002. Single-And multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745. http://dx.doi.org/10.1128/AAC.46.3. 739-745.2002.
19. Marr KA, Laverdiere M, Gugel A, Leisenring W. 2005. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis. 40:1762-1769. http://dx.doi.org/10.1086/429921.
20. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. 2009. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-951. http://dx.doi.org/10.1182/blood-2009-03-209262.
21. Estey EH. 2012. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87:89-99. http://dx.doi.org/10. 1002/ajh.22246.